GeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024. In the quarter to June 2026, revenue grew 11.4%, EPS fell 257.9%, free cash flow fell 585.6% and total debt rose 87.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow WGS
GeneDx Holdings Corp. (WGS) P/E ratio
GeneDx Holdings Corp. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1,893× (September 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 979× | (25.73%) |
| 19 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| WGS GeneDx Holdings Corp. | n/m |
| CSTL Castle Biosciences, Inc. compare | n/m |
| NEO NeoGenomics, Inc. compare | n/m |
| PSNL Personalis, Inc. compare | n/m |
| ADPT Adaptive Biotechnologies Corporation compare | n/m |
| OPK OPKO Health, Inc. compare | n/m |
| CDNA CareDx, Inc. compare | 29.7× |
| VCYT Veracyte, Inc. compare | 29.9× |
| BLLN BillionToOne, Inc. compare | 95.0× |
| Diagnostics & Research industry median | 35.6× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)